Search Result

Results for "

full activator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Androgen Receptor (1) Apoptosis (1) Arrestin (1) ATF6 (1) Btk (1) Cannabinoid Receptor (2) Dopamine Receptor (1) Endogenous Metabolite (1) Estrogen Receptor/ERR (6) Glucokinase (1) Histamine Receptor (1) Isotope-Labeled Compounds (3) Kisspeptin Receptor (1) mAChR (1) nAChR (2) NF-κB (1) p38 MAPK (1) PARP (1) PPAR (2) Prostaglandin Receptor (1) Protease Activated Receptor (PAR) (1) Src (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Trace Amine-associated Receptor (TAAR) (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (4) Endocrinology (7) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (6)

By Targets:

Adrenergic Receptor (1)

Androgen Receptor (1)

Apoptosis (1)

Arrestin (1)

ATF6 (1)

Btk (1)

Cannabinoid Receptor (2)

Dopamine Receptor (1)

Endogenous Metabolite (1)

Estrogen Receptor/ERR (6)

Glucokinase (1)

Histamine Receptor (1)

Isotope-Labeled Compounds (3)

Kisspeptin Receptor (1)

mAChR (1)

nAChR (2)

NF-κB (1)

p38 MAPK (1)

PARP (1)

PPAR (2)

Prostaglandin Receptor (1)

Protease Activated Receptor (PAR) (1)

Src (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

Trace Amine-associated Receptor (TAAR) (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (4)

Endocrinology (7)

Inflammation/Immunology (3)

Metabolic Disease (4)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144287

Glucokinase activator 3	Glucokinase	Endocrinology
Glucokinase activator 3 is a potent and full Glucokinase (GK) activator with an AC₅₀ of 38 nM. Glucokinase activator 3 has the potential for the research of type 2 diabetes .

HY-P10489

Kisspeptin-14 human	Kisspeptin Receptor	Others Cancer
Kisspeptin-14 human is a peptide hormone encoded by the KiSS-1 gene. Kisspeptin-14 human, along with several other similar peptide hormones, is produced from a common precursor protein by cleavage by different proteases. Kisspeptin-14 human has the same receptor binding efficiency and potency as full-length kisspeptin. Kisspeptin-14 human binds to its receptor GPR54 and is able to activate this G protein-coupled receptor and activate multiple intracellular signaling pathways. Kisspeptin-14 human can be used to study reproductive development and tumor metastasis .

HY-W654077

Bisphenol AF-d4 BPAF-d₄; 4,4'-(Perfluoropropane-2,2-diyl)diphenol-d₄	Estrogen Receptor/ERR	Endocrinology
Bisphenol AF-d₄ is the isotope labelled analog of Bisphenol AF (HY-W013782). Bisphenol AF is a full agonist for the estrogen receptor. Bisphenol AF acts as an endocrine-disrupting chemical (EDC), activating estrogen through the estrogen receptor Era. Bisphenol AF-d₄ can be used for the research of endocrinology and cancer .

HY-162081

BTK-IN-32	Btk	Cancer
BTK-IN-32 (compound C2) is a potent inhibitor of BTK. BTK-IN-32 activates full-length BTK and smaller multidomain BTK fragments instead of the isolated kinase domain .

HY-128344

BR102375	PARP Apoptosis	Metabolic Disease
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC₅₀ value of 0.28 μM and A_max ratio of 98% .

HY-108991

T-0509 (-)-T-0509	Adrenergic Receptor	Cardiovascular Disease
T-0509 ((-)-T-0509) is a selective full agonist of the β₁ receptor. T-0509 activates the cAMP signaling pathway through the β₁ receptor and enhances myocardial contractility .

HY-P2380

PAR3 (1-6) (human) TFRGAP	Protease Activated Receptor (PAR)	Inflammation/Immunology
PAR3 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) activates p42/44 MAPK signaling in fibroblasts expressing PAR1, but not PAR3, an effect that can be blocked by the PAR1 antagonist RWJ 56110.

HY-142972

19(S)-HETE	Prostaglandin Receptor	Cardiovascular Disease
19(S)-HETE is an arachidonic acid metabolite produced by cytochrome P450 enzymes. 19(S)-HETE is a full orthosteric agonist of the prostacyclin (IP) receptor with an EC₅₀ value of 567 nM. 19(S)-HETE inhibits platelet activation and relaxation of vessels .

HY-158104

LPPM-8	ATF6	Others
LPPM-8 is a ligand of Med25 and an inhibitor of Med25 protein-protein interactions (PPIs). LPPM-8 engages Med25 through interaction with the H2 face of its Activator Interaction Domain and stabilizes full-length protein in the cellular proteome. LPPM-8 is an orthosteric inhibitor of H2-binding transcriptional activators (such as ATF6a). LPPM-8 can be used for studying Med25 and Mediator complex biology .

HY-146731

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

HY-145604

Vicasinabin RG7774	Cannabinoid Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC₅₀ values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization .

HY-119486A

(Rac)-Tavapadon (Rac)-PF-06649751; (Rac)-CVL-751	Dopamine Receptor Arrestin	Neurological Disease
(Rac)-Tavapadon ((Rac)-PF-06649751) is a potent and selective noncatechol dopamine D1 receptor agonist. (Rac)-Tavapadon displays potent full agonism in the GS activation assay as well as partial agonism in the β-arrestin2 recruitment assay (GS-cAMP, EC₅₀=0.8 nM; β-arrestin2, EC₅₀=68 nM). (Rac)-Tavapadon has antiparkinsonian activity .

HY-135483A

AR-R17779 hydrochloride	nAChR	Neurological Disease
AR-R17779 hydrochloride is a potent and selective full agonist of nAChR, with K_is of 92 and 16000 nM for α7 and α4β2 subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity. AR-R17779 hydrochloride can reduce inflammation by activating antiinflammatory cholinergic (vagal) pathways .

HY-W909173

TAAR1 agonist 2	Trace Amine-associated Receptor (TAAR) Histamine Receptor mAChR	Neurological Disease
TAAR1 agonist 2 (compound 30) is a full agonist of trace amine-associated receptor 1 (TAAR1) (pEC₅₀=7.5). TAAR1 agonist 2 also exhibits agonist activity at H1 receptors and activates several members of the muscarinic acetylcholine receptor family, such as the M2 receptor (pEC₅₀=5). TAAR1 agonist 2 can be used in the study of neuropsychiatric diseases .

HY-123942

Diprovocim 5+ Cited Publications	Toll-like Receptor (TLR) TNF Receptor p38 MAPK NF-κB	Inflammation/Immunology Cancer
Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC₅₀=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC₅₀=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses .

HY-135581

Raloxifene 6-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-110252

Salvinorin B	Endogenous Metabolite	Others
Salvinorin B is a salvinorin, and its analog Salvinorin A is a selective full agonist of κ-opioid receptor (KOPr). Salvinorin A derivative β-tetrahydropyran Salvinorin B also has KOPr agonist activity, activates downstream signaling pathways by binding to KOPr, inhibits pain transmission and reduces inflammatory response, and has central penetrability. Salvinorin B can be used for the study of neuropathic pain (such as paclitaxel-induced pain) and inflammatory diseases[1][2].

HY-135582

Raloxifene 4'-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-148922

PPARα/γ agonist 2	PPAR	Metabolic Disease
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC₅₀ values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .

HY-118504

Sulfoxaflor	nAChR	Neurological Disease
Sulfoxaflor is an orally active full agonist of insect nicotinic acetylcholine receptors (nAChRs), targeting the α-bungarotoxin-insensitive nAChR1 and nAChR2 subtypes. Sulfoxaflor binding to nACh is not inhibited by d-Tubocurarine (HY-125901), but is partially inhibited by Mecamylamine (HY-B1395A). Sulfoxaflor induces inward currents by activating nAChRs, leading to insect neurotoxicity. Sulfoxaflor can be used in the research of agricultural pest control, pesticide toxicology, insect neural receptor pharmacology, etc .

HY-107024

Osteogenic Growth Peptide (10-14) OGP(10-14); Historphin	Src	Others
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor .

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium	Isotope-Labeled Compounds Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-150030

CB1/2 agonist 4	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 4 is a full CB1 agonist and CB2 partial agonist with EC₅₀ values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with K_i values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and TRPV1 receptor with values of IC₅₀ and EC₅₀ is 0.8 μM and 0.12 μM, respectively .

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium	Isotope-Labeled Compounds Estrogen Receptor/ERR	Endocrinology
Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-117669

VPC-14228	Androgen Receptor	Cancer
VPC-14228 is an inhibitor that selectively targets androgen receptor DNA binding domain (AR-DBD). VPC-14228 inhibits the interaction between AR and DNA, thereby blocking AR-mediated transcriptional activation. VPC-14228 does not rely on nuclear localization inhibition, but rather inhibits the activity of full-length AR and splice variant AR-V7 by interfering with AR binding to chromatin. And VPC-14228 has high selectivity for other nuclear receptors such as ER and PR. VPC-14228 can be used in the study of prostate cancer [2].

HY-135582S

Raloxifene 4'-glucuronide-d4	Estrogen Receptor/ERR Isotope-Labeled Compounds	Endocrinology
Raloxifene 4'-glucuronide-d₄ is deuterated labeled Raloxifene 4'-glucuronide (HY-135582). Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

Cat. No.	Product Name	Target	Research Area

HY-P10489

Kisspeptin-14 human	Kisspeptin Receptor	Others Cancer
Kisspeptin-14 human is a peptide hormone encoded by the KiSS-1 gene. Kisspeptin-14 human, along with several other similar peptide hormones, is produced from a common precursor protein by cleavage by different proteases. Kisspeptin-14 human has the same receptor binding efficiency and potency as full-length kisspeptin. Kisspeptin-14 human binds to its receptor GPR54 and is able to activate this G protein-coupled receptor and activate multiple intracellular signaling pathways. Kisspeptin-14 human can be used to study reproductive development and tumor metastasis .

HY-107024

Osteogenic Growth Peptide (10-14) OGP(10-14); Historphin	Src	Others
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor .

HY-P2380

PAR3 (1-6) (human) TFRGAP	Protease Activated Receptor (PAR)	Inflammation/Immunology
PAR3 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) activates p42/44 MAPK signaling in fibroblasts expressing PAR1, but not PAR3, an effect that can be blocked by the PAR1 antagonist RWJ 56110.

HY-158104

LPPM-8	ATF6	Others
LPPM-8 is a ligand of Med25 and an inhibitor of Med25 protein-protein interactions (PPIs). LPPM-8 engages Med25 through interaction with the H2 face of its Activator Interaction Domain and stabilizes full-length protein in the cellular proteome. LPPM-8 is an orthosteric inhibitor of H2-binding transcriptional activators (such as ATF6a). LPPM-8 can be used for studying Med25 and Mediator complex biology .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-110252

Salvinorin B	Structural Classification Terpenoids Labiatae Encelia stenophylla Greene Source classification Diterpenoids Plants	Endogenous Metabolite
Salvinorin B is a salvinorin, and its analog Salvinorin A is a selective full agonist of κ-opioid receptor (KOPr). Salvinorin A derivative β-tetrahydropyran Salvinorin B also has KOPr agonist activity, activates downstream signaling pathways by binding to KOPr, inhibits pain transmission and reduces inflammatory response, and has central penetrability. Salvinorin B can be used for the study of neuropathic pain (such as paclitaxel-induced pain) and inflammatory diseases[1][2].

Cat. No.	Compare	Product Name	Species	Source

HY-P701098

	STAT3 Protein, Human (Full Length, His) STAT3; signal transducer and activator of transcription 3 (acute-phase response factor); signal transducer and activator of transcription 3; APRF	Human	E. coli
	STAT3 is a signal transducer and transcriptional activator that coordinates diverse cellular processes in response to growth factors and cytokines such as interleukin-6 and KITLG/SCF. Upon activation, STAT3 recruits coactivators to target gene promoters, thereby affecting proliferation, differentiation, and immune responses. STAT3 Protein, Human (Full Length, His) is the recombinant human-derived STAT3 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W654077

Bisphenol AF-d4
Bisphenol AF-d₄ is the isotope labelled analog of Bisphenol AF (HY-W013782). Bisphenol AF is a full agonist for the estrogen receptor. Bisphenol AF acts as an endocrine-disrupting chemical (EDC), activating estrogen through the estrogen receptor Era. Bisphenol AF-d₄ can be used for the research of endocrinology and cancer .

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium
Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

Raloxifene 6-glucuronide-d4 lithium

Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium
Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

Raloxifene 4'-glucuronide-d4 lithium

Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-135582S

Raloxifene 4'-glucuronide-d4
Raloxifene 4'-glucuronide-d₄ is deuterated labeled Raloxifene 4'-glucuronide (HY-135582). Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

Raloxifene 4'-glucuronide-d4

Raloxifene 4'-glucuronide-d₄ is deuterated labeled Raloxifene 4'-glucuronide (HY-135582). Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82211

	GLI3 Antibody (YA1956) GLI3; Transcriptional activator GLI3; GLI3 form of 190 kDa; GLI3-190; GLI3 full length protein; GLI3FL	WB, ICC/IF	Human
	GLI3 Antibody (YA1956) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1956), targeting GLI3, with a predicted molecular weight of 170 kDa (observed band size: 190 kDa). GLI3 Antibody (YA1956) can be used for WB, ICC/IF experiment in human background.